The study will explore the combination of Elicio's AMP-CD19 with CD19 CAR T cells to treat lymphomas and other B-cell malignancies. AMP-CD19 is a CAR-binding peptide that is modified to traffic into lymph nodes for display on native immune cells.

AMP-CD19 can activate engineered T cells to enhance their persistence and proliferation, as well as increase activity against B-cell malignancies such as diffuse large B-cell lymphoma and acute lymphocytic leukemia.

The research will be led by Dr. Marco Davila, PhD, associate member of the blood and marrow transplant and cellular immunotherapies department and medical director of cell therapies at Moffitt.

Yufan, Abound Bio to develop CAR T cell therapies
Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer...

Atara advances CAR T technology with IND clearance
Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a...

Kite submits BLA for CAR T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel...

Carma Cell Therapies expands phase I trial of cell therapy
Carma Cell Therapies said it has expanded the phase I trial of its Mcy-M11 lead anti-mesothelin messenger RNA chimeric antigen receptor- peripheral blood...